Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 91 of 97, showing 5 Applications out of 482 total, starting on record 451, ending on 455

# Protocol No Study Title Investigator(s) & Site(s)

451.

ECCT/12/04/02   Short-course RPT/INH for latent TB in HIV-infected individuals
    A5279: Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection       
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

452.

ECCT/12/04/01  
    A double-masked randomised placebo-controlled trial of adjuvant topical 5-fluorouracil (5FU) treatment following surgical excision of ocular surface squamous neoplasia.       
Principal Investigator(s)
1. Stephen Gichuhi
Site(s) in Kenya
1. Kenyatta National Hospital (Nairobi City county)
2. PCEA Kikuyu Eye Unit (Kiambu county)
3. Sabatia Eye Hospital (Kakamega county)
4. Kitale District Hospital, Eye Unit (Trans Nzoia county)
5. Homa Bay District Hospital, Eye Unit (Homa Bay county)
 
View

453.

ECCT/12/03/01  
    Role of Fish Oil Omega-3 Fatty Acids on Depression among HIV-Seropositive Pregnant Women in Nairobi: A Randomized Double-blind Controlled Trial   
Principal Investigator(s)
1. Rose Okoyo Opiyo
Site(s) in Kenya
1. Riruta Health Centre (Nairobi City county)
2. Kariobangi North Health Centre (Nairobi City county)
3. Mathare North Health Centre (Nairobi City county)
4. Kayole II Sub-district hospital (Nairobi City county)
 
View

454.

ECCT/12/02/02   HIV/HPV-Adolescent Study
    Immunogenicity and Safety of quadrivalent human Papillomavirus Vaccine in HIV-Infected pre-adolescent girls and boys in Kenya.   
Principal Investigator(s)
1. Dr. Nelly Rwamba Mugo
Site(s) in Kenya
Thika
 
View

455.

ECCT/11/12/04   PENNVAX-G DNA/MVA HIV Vaccine Phase 1 trial
    A Phase I Study of the Safety and Immunogenicity of PENNVAX™-G DNA (Env & Gag) Administered by Intramuscular Biojector® 2000 or by CELLECTRA® Intramuscular Electroporation Device Followed by MVACMDR (HIV-1 CM235 env/ CM240 gag/pol) Boost in Healthy, HIV Uninfected Adults   
Principal Investigator(s)
1. FREDRICK KIPYEGO SAWE
Site(s) in Kenya
KEMRI/Walter Reed Project-Kericho
 
View